Information for medicine and pack size:
Cimzia 200 mg/mL injection solution, 2 x 1 mL syringes

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Rheumatoid arthritis CIMZIA is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients. - combined with MTX in case of either an inadequate response or intolerance to previous therapy with one or more disease-modifying antirheumatic drugs (DMARDs) or - as monotherapy in case of a contraindication or intolerance to MTX (see DOSAGE AND ADMINISTRATION).,CIMZIA has been shown to reduce the rate of progression of joint damage as measured by X-ray, when given in combination with MTX.,CIMZIA in combination with MTX is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX or other DMARDs.,Psoriatic arthritis CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous disease-modifying anti-rheumatic drug therapy (DMARDs) has been inadequate. CIMZIA has been shown to improve physical function.,Ankylosing Spondylitis CIMZIA is indicated for the treatment of adult patients with active, ankylosing spondylitis who have been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug (NSAID).

Table of characteristics

There is one type of pack available.

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site